Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2022-12-02 00:00:00 ET · period of report 2022-12-01 · accession 0001883850-22-000102 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-12-02 | 2022-12-01 | REGN | Landry Robert E | EVP Fin CFO | F - Tax | $760.35 | -1,890 | 29.4K | -6% | -$1.44M |
| D | 2022-12-02 | 2022-12-01 | REGN | Landry Robert E | EVP Fin CFO | M - OptEx | $381.92 | +2,500 | 31.2K | +9% | +$954.8K |
| DM | 2022-12-02 | 2022-12-02 | REGN | Landry Robert E | EVP Fin CFO | S - Sale+OE | $756.66 | -610 | 28.8K | -2% | -$461.6K |
| D | 2022-12-02 | 2022-12-01 | REGN | Landry Robert E | EVP Fin CFO | M - OptEx | $0.00 | -2,500 | 6,800 | -27% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-01 | F | D | 1,890 | $760.35 | 29,354 | D | — | — | |
| 2 | Common | Common Stock | 2022-12-01 | M | A | 2,500 | $381.92 | 31,244 | D | — | — | |
| 3 | Common | Common Stock | 2022-12-02 | S | D | 582 | $756.50 | 28,772 | D | — | — | |
| 4 | Common | Common Stock | 2022-12-02 | S | D | 12 | $760.19 | 28,744 | D | — | — | |
| 5 | Common | Common Stock | 2022-12-02 | S | D | 16 | $759.90 | 28,756 | D | — | — | |
| 6 | Derivative | Non-Qualified Stock Option (right to buy) | 2022-12-01 | M | D | 2,500 | $0.00 | 6,800 | D | $381.92 · — to 2026-12-16 | 2,500 Common Stock | (F2) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |